Bristol Myers Squibb

Bristol Myers Squibb is an American biopharmaceutical company that develops and sells medicines, with major portfolios in cancer, immunology, and cardiovascular disease.

Nivolumab: Nivolumab is a monoclonal antibody that blocks the immune checkpoint protein PD-1 to treat several cancers. This checkpoint inhibitor is one of Bristol Myers Squibb’s signature cancer medicines.
Bristol-Myers Company: Bristol-Myers Company was an American pharmaceutical company founded in 1887 by William McLaren Bristol and John Ripley Myers. This predecessor supplied one half of the company’s name and corporate lineage.
Drug discovery: Drug discovery is the process of finding and optimizing compounds or biological agents that may treat disease. It begins the path from biological insight to a potential company medicine.
Merck & Co.: Merck & Co. is an American pharmaceutical company known for medicines and vaccines, including the cancer immunotherapy pembrolizumab. Merck competes with Bristol Myers Squibb in oncology and immune-checkpoint therapy.
Ipilimumab: Ipilimumab is a monoclonal antibody that blocks CTLA-4, an immune checkpoint, and is used to treat several cancers. It is paired with nivolumab in important Bristol Myers Squibb immunotherapy regimens.
E. R. Squibb & Sons: E. R. Squibb & Sons was an American pharmaceutical company founded in 1858 by Edward Robinson Squibb. Its 1989 merger with Bristol-Myers created the combined company.
Clinical trial: A clinical trial is a study in people designed to assess a medical intervention’s safety or effects. Bristol Myers Squibb tests candidate medicines through staged human studies.
Pfizer: Pfizer is an American pharmaceutical company that develops and sells medicines and vaccines across multiple therapeutic areas. Its broader portfolio and scale offer a comparison with Bristol Myers Squibb’s focused biopharmaceutical strategy.
Apixaban: Apixaban is an oral anticoagulant that inhibits factor Xa and helps prevent blood clots and strokes. Eliquis, the company’s major anticoagulant, extends its business beyond oncology.
Celgene: Celgene was an American biotechnology company focused on cancer and inflammatory diseases before its 2019 acquisition by Bristol Myers Squibb. Its acquisition substantially expanded the company’s oncology and hematology business.

Linked from 5 pages